ATE123807T1 - Verstärkte aktivierung von lak-zellen durch behandlung menschlicher peripherer mononuklearer blutzellen mit aminosäuren. - Google Patents

Verstärkte aktivierung von lak-zellen durch behandlung menschlicher peripherer mononuklearer blutzellen mit aminosäuren.

Info

Publication number
ATE123807T1
ATE123807T1 AT90911159T AT90911159T ATE123807T1 AT E123807 T1 ATE123807 T1 AT E123807T1 AT 90911159 T AT90911159 T AT 90911159T AT 90911159 T AT90911159 T AT 90911159T AT E123807 T1 ATE123807 T1 AT E123807T1
Authority
AT
Austria
Prior art keywords
cells
amino acids
human peripheral
treating human
peripheral mononuclear
Prior art date
Application number
AT90911159T
Other languages
English (en)
Inventor
Joseph David Irr
Kam Leung
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Application granted granted Critical
Publication of ATE123807T1 publication Critical patent/ATE123807T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT90911159T 1989-07-21 1990-07-12 Verstärkte aktivierung von lak-zellen durch behandlung menschlicher peripherer mononuklearer blutzellen mit aminosäuren. ATE123807T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/383,221 US5108760A (en) 1989-07-21 1989-07-21 Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides

Publications (1)

Publication Number Publication Date
ATE123807T1 true ATE123807T1 (de) 1995-06-15

Family

ID=23512221

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911159T ATE123807T1 (de) 1989-07-21 1990-07-12 Verstärkte aktivierung von lak-zellen durch behandlung menschlicher peripherer mononuklearer blutzellen mit aminosäuren.

Country Status (8)

Country Link
US (1) US5108760A (de)
EP (1) EP0483223B1 (de)
JP (1) JPH05504882A (de)
AT (1) ATE123807T1 (de)
AU (1) AU5957090A (de)
CA (1) CA2063813A1 (de)
DE (1) DE69020157T2 (de)
WO (1) WO1991002050A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374549A (en) * 1991-01-31 1994-12-20 Terumo Corporation Process of enriching adherent CD4+ T cells from monocyte depleted peripheral blood mononuclear cells with interleukin 2 and interleukin 4
JP4308350B2 (ja) * 1998-11-27 2009-08-05 小林製薬株式会社 シイタケ菌糸体抽出物を含有するｌａｋ活性スクリーニング物質およびそれを用いたｌａｋ活性スクリーニング法
DE19929809A1 (de) 1999-06-30 2001-01-04 Ticona Gmbh Kontinuierliches Verfahren zur Herstellung eines amorphen Polyolefins mit breiter Molmassenverteilung und einheitlicher Glastemperatur
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
CN1628167A (zh) * 2001-11-22 2005-06-15 医学基因公司 白细胞介素－2基因转移的淋巴因子活化的杀伤细胞
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
US7332158B2 (en) * 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US20060057121A1 (en) * 2004-09-10 2006-03-16 Demao Yang Compositions and treatments using ex vivo activated cells for myelosuppressed patients
IT1403257B1 (it) * 2010-12-06 2013-10-17 Intercos Italiana Composizioni cosmetiche contenenti composti con azione anti-glicazione, da usare per prevenire e rallentare il processo di invecchiamento cutaneo
US20190298766A1 (en) * 2018-03-29 2019-10-03 Demao Yang Cell therapy for patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752601A (en) * 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US4883662A (en) * 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4690916A (en) * 1984-11-13 1987-09-01 Syntex (U.S.A.) Inc. Nona and decapeptide analogs of LHRH useful as LHRH antagonists
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4752602A (en) * 1985-09-09 1988-06-21 Board Of Regents, The University Of Texas System Dipeptide alkyl esters and their uses
US4849329A (en) * 1986-05-30 1989-07-18 E. I. Du Pont De Nemours And Company Process for preparing lymphokine activated killer cells
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
EP0483216B1 (de) * 1989-07-21 1995-01-25 Terumo Kabushiki Kaisha Verfahren zur herstellung menschlicher adhärenter lymphokin-aktivierter killerzellen (alak)

Also Published As

Publication number Publication date
US5108760A (en) 1992-04-28
DE69020157T2 (de) 1995-11-16
DE69020157D1 (de) 1995-07-20
AU5957090A (en) 1991-03-11
CA2063813A1 (en) 1991-01-22
WO1991002050A1 (en) 1991-02-21
JPH05504882A (ja) 1993-07-29
EP0483223B1 (de) 1995-06-14
EP0483223A1 (de) 1992-05-06

Similar Documents

Publication Publication Date Title
BR9607894A (pt) Processo para tratar tumores
JPS5598118A (en) Preparation of type-2 interferon and drug containing the same
ATE106740T1 (de) Herstellung von t-zellen und t-zellmembranen, verwendbar zur verhütung und behandlung von autoimmunkrankheiten.
ES8106407A1 (es) Procedimiento para el tratamiento de superficies hidrofobas
PT87086A (pt) Active specific immune suppression
PT85285A (en) Process for producing il-6 and of pharmaceutical compositions containing the same
ATE123807T1 (de) Verstärkte aktivierung von lak-zellen durch behandlung menschlicher peripherer mononuklearer blutzellen mit aminosäuren.
NO844579L (no) Enzymresistente immunomodulerende peptider.
ES2007341A6 (es) Un procedimiento para producir m-csf
NO872395D0 (no) Fremgangsmaate for fremstilling av biologisk aktiv plasminogenaktivator.
ATE176683T1 (de) Tumorizide t-lymphozyten
ATE98869T1 (de) Pharmazeutisches mittel fuer behandlung von menschlichem krebs und verfahren zu seiner herstellung.
DE59002154D1 (de) Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid oder ethambutol als aktive wirkstoffe.
Clark et al. Evidence for a conformational change in nerve membrane with depolarization
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
DE69012999D1 (de) Schutz zytolytischer aktivität von nk-zellen in peripheren blut-mononuklearzellen.
EP0257962A3 (de) Verfahren zur Behandlung von Umkreisblut für die Verbesserung der lymphokinaktivierten Töterzell-Immuntherapie
ATE110278T1 (de) Verfahren und zubereitung für die behandlung von hiv-infizierten säugetieren.
Ling Immune surveillance of lymphoid tissue. A biological role for the mixed lymphocyte reaction
PT80214B (en) Process for the preparation of a pharmaceutical composition containing 9alpha,11beta-dichloro 16alpha-methyl 21-oxycarbonyldicyclohexyl-methyloxi-pregne-1,4-diene 3,20-dione as active agent and an inert product as excipient appropriate to permit r said composition to be used in the rectum or colon
Gruner et al. Stimulation of the recruitment of epidermal Langerhans cells by splenopentin
Petrov et al. Nature of a humoral factor of bone marrow stimulating antibody production
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
Moore et al. SERUM HEMATOPOIETIC INHIBITORS AND TUMOR NECROSIS FACTOR

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties